B
ALXO icon

Bailard’s ALX Oncology ALXO Stock Holding History

Bailard’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-15,510
Closed -$125K – 665
2022
Q2 		$125K Buy
+15,510
New +$169K ﹤0.01% 644

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Bailard's ALXO Position: Q3 2022 in Review

Bailard sold out of ALX Oncology (ALXO) in Q3 2022, closing a stake of 15,510 shares — an estimated $125K sold.

Bailard first reported a position in ALXO in Q2 2022 and held it in 1 quarter. The position peaked at $125K in Q2 2022. 99 funds tracked by Wall St. Rank hold ALXO as of Q3 2022.

  • Bailard reported no remaining ALX Oncology position as of Q3 2022 after selling out during the quarter.
  • Bailard sold 15,510 ALX Oncology shares in Q3 2022, an estimated $125K.
  • Bailard first reported a position in ALX Oncology in Q2 2022 and held it in 1 quarter.
  • Bailard's ALX Oncology position peaked at $125K in Q2 2022.
  • 99 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2022.

Based on Bailard's 13F filing for Q3 2022, filed 18 Oct 2022.